Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2

BACKGROUND: Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-ly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatr Blood Cancer
Hauptverfasser: Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Lu, Xiaomin, Devidas, Meenakshi, Reid, Joel M., Goldenberg, David M., Wegener, William A., Zeng, Hui, Whitlock, James A., Adamson, Peter C., Hunger, Stephen P., Carroll, William L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701208/
https://ncbi.nlm.nih.gov/pubmed/25732247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25454
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge